Advertisement

Organisation › Details
Biocartis (Group)
Biocartis aims to improve healthcare outcomes by enabling the practice of personalized medicine anywhere, anytime. Biocartis' ambition is to establish a new gold standard in diagnostic testing. Biocartis provides innovative research and diagnostic systems with multiplex detection and simplified workflows which require less hands-on time and minimize sample requirements (especially for tumor biopsies). Additionally, Biocartis develops assays which have high clinical utility and compelling health economic value. Oncology is the primary focus of Biocartis as this is one of the greatest unmet needs for personalized medicine. Biocartis is well suited to address the growing need for individualized diagnosis and treatment of cancer patients. Biocartis is a rapidly growing company; to date Biocartis staff includes over 140 people. The company has raised in total EUR 125 million in equity. *
![]() |
Start | 2007-01-01 established |
![]() |
Industry | molecular diagnostics |
Industry 2 | cancer test | |
![]() |
Person | Verrelst, Herman (Biocartis 201709– CEO before Agilent + Cartagenia + Medicim + Data4s) |
Person 2 | Welten, Ewoud (Biocartis 201607 CFO) | |
![]() |
Region | Mechelen |
Country | Belgium | |
Street | 11 B3 Gen. De Wittelaan | |
City | 2800 Mechelen | |
Tel | +32-15-632-600 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | D: 101 to 500 (2018-12-31) |
Currency | EUR | |
Annual sales | 37,732,000 (operating income, consolidated (2019) 2019-12-31) | |
Profit | -64,068,000 (2019-12-31) | |
Cash | 178,725,000 (2019-12-31) | |
* Document for �About Section�: | ||
Record changed: 2020-05-17 |
Advertisement

More documents for Biocartis (Group)
- [1] Biocartis Group N.V.. (10/6/20). "Press Release: Biocartis Announces Market Release of SeptiCyte RAPID Test on Idylla". Mechelen....
- [2] Biocartis Group N.V.. (9/30/20). "Press Release: Biocartis Receives EUR 1.2 Million Grant for Development of Highly Innovative Idylla GeneFusion Assay". Mechelen....
- [3] Biocartis Group N.V.. (9/1/20). "Press Release: Biocartis Expands Collaboration with LifeArc". Mechelen & London....
- [4] Biocartis Group N.V.. (3/5/20). "Press Release: Biocartis Announces New Immuno-Oncology Project with Bristol-Myers Squibb Aimed at Registration of Idylla MSI test in China". Mechelen....
- [5] Biocartis Group N.V.. (3/5/20). "Press Release: Biocartis Announces 2019 Results and 2020 Outlook". Mechelen....
- [6] Biocartis Group N.V.. (1/27/20). "Press Release: Biocartis Announces Resignation of CFO". Mechelen....
- [7] Biocartis Group N.V.. (6/1/19). "Press Release: Biocartis and Kite Sign Agreement for Development of Assays Supporting Kite's Therapies". Mechelen....
- [8] Biocartis Group N.V.. (4/25/19). "Press Release: Biocartis Q1 2019 Business Update". Mechelen....
- [9] Biocartis Group N.V.. (4/23/19). "Press Release: Biocartis Announces Global Collaboration with Covance". Mechelen....
- [10] Biocartis Group N.V.. (1/23/19). "Press Release: Biocartis Successfully Raises EUR 55.50 Milion in an Equity Placement [NOT FOR US, AU, CA, JP, ZA, et al.]". Mechelen....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement
![Picture [iito] Back into Ad 650x80px](/banner/iito-business-intelligence-20200507-650-080-summer-banner-series-back-into-ad.jpg)
» top